Dr Ryder is a Consultant Hepatologist and cares for patients with a wide range of liver disorders. His specific areas of interest are viral hepatitis (B+C) and their treatment, autoimmune liver diseases, alcohol related liver disease and liver cancer. He also undertakes ERCP, which is liver-related endosocpy.
Dr Ryder has a strong commitment to improving healthcare through research and helps to run a substantial number of clinical trials in these areas.
He also has a management role as Director of Research for Nottingham University Hospitals NHS Trust.
Dr Ryder sees and treats NHS patients at the Nottingham NHS Treatment Centre.
Current NHS or research position
Consultant Hepatologist, Nottingham University Hospitals NHS Trust
Director of Research and Innovation, Nottingham University Hospitals NHS Trust
Professor of Hepatology, University of Nottingham
Year of first medical qualification
Special clinical interests
Viral hepatitis: Dr Ryder has been an author on national and European guidelines on the management of hepatitis C infection and has been expert advisor to NICE on 4 single Technology Appraisals of new therapies (2012-2015).
As part of a number of collaborative groups, HCV UK, STOP HCV and The Trent HCV Cohort study, Dr Ryder has helped produce a series of papers describing the epidemiology, natural history and factors influencing treatment of hepatitis C virus infection in the UK. This data were used (and acknowledged) in Department of Health Hepatitis C Strategy for England and Wales (2002), and 5 annual reports on Hepatitis C arising from the Department of Health Action Plan, produced by the Health Protection Agency (latest 2014). As such they have both informed national policy on hepatitis C management and been influential in change of clinical management and therapy.
HCV UK was founded with an award of a £3 million grant to establish a national HCV cohort from the Medical Research Foundation (charitable arm of MRC) and STOP HCV has generated a further £2.5 million.
Dr Ryder has been an author on national and European guidelines on the management of hepatitis C infection and has been an expert advisor to NICE on 4 single Technology Appraisals of new therapies (2012-2015).
Autoimmune liver disease
Dr Ryder has been a part of a further national collaboration in autoimmune liver disease funded by a series of MRC grants, looking initially at the genetics of autoimmune lever disease. More recently this has involved collaboration with NIHR and the pharmaceutical industry to develop a clinical trials infrastructure to deliver a number of new promising agents in clinical trials while ensuring access for patients with relatively rare disorders. Nottingham is the East Midlands hub for these studies and is currently recruiting to a number of commercial trials in this area.
Alcohol related liver disease
Alcohol related liver disease is the most common liver related problem by some distance yet has had little research funding into treatments. Dr Ryder was a co-applicant in a major study of therapy in alcoholic hepatitis which was funded by HTA (£1.7 million) and recruited from 60 UK hospitals. Nottingham was the third largest recruiting centre and the study has now been published. This is by some way the largest RCT in alcohol related liver disease worldwide. The group continue to develop new protocols to find better treatments for ALD.
This work contributed to the award of the Nottingham Biomedical Research Unit for translational research in 2008 and its renewals including the current BRC successful application from April 2017.
Dr Ryder has a long standing interest in primary liver cancer and its treatment. He wrote the national Guidelines for the management of primary liver cell (Hepatocelullar) cancer.
Current memberships of professional, national and regional bodies
British Society of Gastroenterology
British association for the study of the Liver
Dr Ryder has had a specific role to enhance engagement with commercial trials and built research links with industry, this resulted in an NIHR at 10 award for being one of England’s top 3 recruiters to commercial studies and enhancing the number of commercial hepatology studies on the portfolio. As Director of Research and Innovation in Nottingham and Director of the Clinical Research Facility, he has helped build the research infrastructure integral to the BRC award.
Dr Ryder has published over 100 research and review articles.